
Opinion|Videos|January 17, 2025
Overview and Benefits of Port Delivery System with Ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide an overview of the port delivery system with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery system with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Uveitis risk rises as immune checkpoint inhibitor use expands
2
Laru-zova sustains visual function improvements at 12 months in XLRP gene therapy trial
3
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
4























